Fowl Adenovirus Fiber-2 Vaccine Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against fowl adenovirus infection face challenges in achieving high immunological efficacy due to difficulties in culturing the virus, variations among isolated strains, and bio-safety risks associated with incomplete inactivation, leading to inadequate protection and safety concerns.
Innovation Solution
A vaccine composition incorporating the fowl adenovirus Fiber-2 protein, either as a subunit antigen or through a live vector recombination, is developed, which includes a preparation method involving gene cloning, transformation, expression, purification, and treatment with a non-ionic surfactant, followed by mixing with an adjuvant and emulsification to enhance immunogenicity and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole virus vaccines are used, then immunization effect can be achieved, but bio-safety risks occur due to incomplete inactivation
Solution Approach 1:
The patent extracts the immunogenic components (Fiber-2 protein and hexon protein) from the complete virus structure to create subunit vaccines. This extraction eliminates the bio-safety risks associated with incomplete inactivation while preserving the essential immunogenic properties needed for vaccine effectiveness.
Solution Approach 2:
The patent segments the virus into specific immunogenic proteins (Fiber-2 and hexon) to create recombinant subunit vaccines. By dividing the virus into functional components, the invention achieves safe inactivation of pathogenic elements while maintaining immunogenicity through controlled expression of protective antigens.
2Object-affected harmful factors
If subunit vaccines with hexon antigen are used, then bio-safety is improved, but immunological efficacy becomes insufficient
Solution Approach 1:
The patent combines multiple immunogenic proteins (Fiber-2 and hexon) into a single recombinant vaccine formulation. This merging of complementary antigens enhances immunological efficacy by targeting multiple viral components simultaneously, thereby improving protective immunity while maintaining the bio-safety advantages of subunit vaccines.
Solution Approach 2:
The patent creates a composite vaccine containing Fiber-2 protein and hexon protein as immunogenic components. This composite approach integrates multiple antigenic determinants that work synergistically to elicit stronger and broader immune responses compared to single-antigen vaccines.
3Ease of manufacture
If traditional virus culturing methods are used, then vaccine production can proceed, but high-titer virus is difficult to obtain due to strain variations
Solution Approach 1:
The patent uses recombinant DNA technology to copy and express specific viral genes (Fiber-2 and hexon) in host cells. This copying approach bypasses the need for traditional virus culturing and eliminates variability associated with different viral strains, ensuring consistent production of standardized immunogenic proteins with predictable potency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine composition provides 100% protection against fowl adenovirus infection, is safe for immunization, and can be used in combination with other pathogens to offer comprehensive protection against various genotypes, addressing the limitations of existing vaccines.
Implementation Method 1
treating the purified recombinant fowl adenovirus protein with a non-ionic surfactant
Implementation Method 2
mixing the fowl adenovirus protein with an adjuvant based on a certain ratio and emulsifying the resulting mixture
Data Source
AI summary
The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.